Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock

Nuvation Bio Inc. (NYSE:NUVB) is one of the 12 Best Stocks to Buy According to Billionaire David Abrams.

Nuvation Bio Inc. (NYSE:NUVB) has been featured in the 13F portfolio of Abrams Capital Management since the first quarter of 2021. The stake comprises 3.81 million shares. The fund has not made any changes to this position for the past five years. Nuvation is a clinical-stage biopharmaceutical company that focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. In earnings for the fourth quarter of 2025, the firm announced several strategic advances, including approval and partnerships for IBTROZI in China and Japan, and a new partnership with Eisai for Europe and other territories, with the goal to submit for European approval in the first half of 2026.

READ MORE: Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress.

Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month

Colleen Sjogren, the CCO of Nuvation Bio Inc. (NYSE:NUVB), spoke during the earnings call, highlighting that IBTROZI treated 432 new patients from approval through year-end and is being prescribed across both TKI-naive and pretreated populations. Meanwhile, Philippe Sauvage, the CFO of the biotech company, underlined that out of the $41.9 million in fourth-quarter revenue, $15.7 million was from IBTROZI. Although the management of the firm did not provide specific 2026 revenue guidance, it did underscore confidence in continued first-line patient growth and IBTROZI’s expanding presence.

While we acknowledge the risk and potential of NUVB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NUVB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.